These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11700394)

  • 1. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
    Bernard GR; Ely EW; Wright TJ; Fraiz J; Stasek JE; Russell JA; Mayers I; Rosenfeld BA; Morris PE; Yan SB; Helterbrand JD
    Crit Care Med; 2001 Nov; 29(11):2051-9. PubMed ID: 11700394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E; Reinhart K; Svoboda P; Seibert A; Olthoff D; Dal Nogare A; Postier R; Hempelmann G; Butler T; Martin E; Zwingelstein C; Percell S; Shu V; Leighton A; Creasey AA
    Crit Care Med; 2001 Nov; 29(11):2081-9. PubMed ID: 11700399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
    Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
    Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
    Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
    Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.
    de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vroom MB; Meijers JC; Büller HR; Levi M
    Crit Care; 2005 Oct; 9(5):R490-7. PubMed ID: 16277710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human activated protein C for severe sepsis in neonates.
    Kylat RI; Ohlsson A
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD005385. PubMed ID: 22513930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel treatment for severe sepsis: recombinant human protein C (RHAPC)].
    Uszyiński W; Uszyński M; Lisiecki A
    Ginekol Pol; 2005 Nov; 76(11):913-20. PubMed ID: 16566369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human activated protein C for severe sepsis in neonates.
    Kylat RI; Ohlsson A
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005385. PubMed ID: 16625638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
    Brueckmann M; Wizenmann J; Hoffmann U; Seeger M; Bewig B
    Thromb Res; 2003 Mar; 109(5-6):259-63. PubMed ID: 12818248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
    Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
    J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial.
    von Dadelszen P; Magee LA; Benton SJ; Hu Y; Ansermino JM; Carleton B; Carter C; Douglas MJ; Janssen PA; Lee SK; Leung PCK; Li J; MacNab Y; Payne BA; Peng G; Rodger M; Skoll MA; Synnes A; Walley KR; Russell JA
    Pregnancy Hypertens; 2018 Jul; 13():121-126. PubMed ID: 30177038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated).
    Lyseng-Williamson KA; Perry CM
    Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis.
    Maybauer MO; Maybauer DM; Fraser JF; Traber LD; Westphal M; Enkhbaatar P; Cox RA; Huda R; Hawkins HK; Morita N; Murakami K; Mizutani A; Herndon DN; Traber DL
    Crit Care Med; 2006 Sep; 34(9):2432-8. PubMed ID: 16810106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
    Derhaschnig U; Reiter R; Knöbl P; Baumgartner M; Keen P; Jilma B
    Blood; 2003 Sep; 102(6):2093-8. PubMed ID: 12750166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.
    Macias WL; Vallet B; Bernard GR; Vincent JL; Laterre PF; Nelson DR; Derchak PA; Dhainaut JF
    Crit Care Med; 2004 Dec; 32(12):2385-91. PubMed ID: 15599140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation.
    Aoki N; Matsuda T; Saito H; Takatsuki K; Okajima K; Takahashi H; Takamatsu J; Asakura H; Ogawa N;
    Int J Hematol; 2002 Jun; 75(5):540-7. PubMed ID: 12095157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.